DHR
Danaher CorporationHealthcareDiagnostics & ResearchCyclical
$167.16 · 15min delay
β 0.84A steady large-cap cyclical trading near fair value. Frameworks sharply disagree on it.
52-wk low $165.2552-wk high $242.80
Mkt Cap
$118.31B
P/E
—
PEG
1.09
P/B
2.23
Dividend
0.96%
ROE
7.1%
About the business
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.
Who would buy DHR?
Consensus 21/100 · Mixed · Investors are split.
2 5 8
Endorses
· 2 frameworks- Cyclical Value School· Deep Cyclical88/100
Down > 30% from 52-wk high -31.2% clears "< -30.0%".
- Howard Marks· Marks Risk-First83/100
Debt/Equity < 0.5 0.37 clears "< 0.50".
Rejects
· 3 frameworks- Fama / French
Insider activity · Negative
Insider selling outweighs buying
Strength 55/100
4 insiders sold $10.6M on a discretionary basis. Discretionary selling carries more signal than planned disposals, but insiders sell for many non-thesis reasons (taxes, diversification, life events) — do not over-read it. Over the 6M window, insiders are net sellers by 291,331 shares.
In Prism's context
Insider selling is worth flagging but insiders sell for many non-thesis reasons. Read alongside the framework verdict (Fails criteria).
| Insider | Role | Type | Date | Shares | Avg price | Value | Own |
|---|---|---|---|---|---|---|---|
| SPOON ALAN G | Director | Option exercise | May 1, 2026 | 3,298 | $71.88 | $237K | Direct |
| SPOON ALAN G | Director | Open-market sell | May 1, 2026 | 1,358 | $174.67 | $237K | Direct |
| BLAIR RAINER M | Chief Executive Officer | Award / grant | Feb 27, 2026 | 17,566 | $0.00 | $0 | Direct |
| GUTIERREZ-RAMOS JOSE-CARLOS | Officer | Award / grant | Feb 27, 2026 | 6,647 | $0.00 | $0 | Direct |
| GRAY ROBERT BRADLEY | Officer | Award / grant | Feb 27, 2026 | 2,849 | $0.00 | $0 | Direct |
| LEIKEN JONATHAN B | Officer | Award / grant | Feb 27, 2026 | 2,374 | $0.00 | $0 | Direct |
| BOUDA CHRISTOPHER | Officer | Award / grant | Feb 27, 2026 | 1,247 | $0.00 | $0 | Direct |
| COUCHARA GEORGEANN F. | Officer | Award / grant | Feb 27, 2026 | 4,748 | $0.00 | $0 | Direct |
| RILEY CHRISTOPHER PAUL | Officer | Award / grant | Feb 27, 2026 | 6,172 | $0.00 | $0 | Direct |
| SAWYER MONTGOMERY JULIE A | Officer | Award / grant | Feb 27, 2026 | 6,172 | $0.00 | $0 | Direct |
| MILOSEVICH GREGORY M | Officer | Award / grant | Feb 27, 2026 | 4,273 | $0.00 | $0 | Direct |
| GUGINO MATTHEW E. | Chief Financial Officer | Award / grant | Feb 27, 2026 | 3,988 | $0.00 | $0 | Direct |
| MCGREW MATTHEW | Officer | Award / grant | Feb 27, 2026 | 5,935 | $0.00 | $0 | Direct |
| RALES MITCHELL P | Officer and Director | Stock Gift at price 0.00 per share. | Feb 27, 2026 | 71,648 | $0.00 | $0 | Indirect |
| MILOSEVICH GREGORY M | Officer | Option exercise | Feb 19, 2026 | 1,320 | $58.59 | $77K | Direct |
| MILOSEVICH GREGORY M | Officer | Open-market sell | Feb 19, 2026 | 1,320 | $208.01 | $275K | Direct |
| BLAIR RAINER M | Chief Executive Officer | Award / grant | Feb 4, 2026 | 8,474 | $0.00 | $0 | Direct |
| GUTIERREZ-RAMOS JOSE-CARLOS | Officer | Award / grant | Feb 4, 2026 | 1,695 | $0.00 | $0 | Direct |
| ELLIS BRIAN W | Officer | Award / grant | Feb 4, 2026 | 1,695 | $0.00 | $0 | Direct |
| COUCHARA GEORGEANN F. | Officer | Award / grant | Feb 4, 2026 | 1,413 | $0.00 | $0 | Direct |
| RILEY CHRISTOPHER PAUL | Officer | Award / grant | Feb 4, 2026 | 1,046 | $0.00 | $0 | Direct |
| SAWYER MONTGOMERY JULIE A | Officer | Award / grant | Feb 4, 2026 | 848 | $0.00 | $0 | Direct |
| MILOSEVICH GREGORY M | Officer | Award / grant | Feb 4, 2026 | 679 | $0.00 | $0 | Direct |
| MCGREW MATTHEW | Chief Financial Officer | Award / grant | Feb 4, 2026 | 2,684 | $0.00 | $0 | Direct |
| RALES MITCHELL P | Officer and Director | Stock Gift at price 0.00 per share. | Nov 25, 2025 | 22,029 | $0.00 | $0 | Indirect |
| RALES MITCHELL P | Officer and Director | Open-market sell | Nov 25, 2025 | 40,625 | $230.38 | $9.36M | Indirect |
| LIST TERI | Director | Option exercise | Nov 18, 2025 | 3,298 | $71.88 | $237K | Direct |
| LIST TERI | Director | Open-market sell | Nov 18, 2025 | 3,298 | $226.50 | $747K | Direct |
| LEIKEN JONATHAN B | General Counsel | Award / grant | Nov 14, 2025 | 10,172 | $0.00 | $0 | Direct |
Insider activity from Yahoo Finance (quoteSummary: insiderTransactions + netSharePurchaseActivity). Cached 6 hours. · Insiders hold 10.8% of shares outstanding.
Net 6M: -291,331 sh
Price history
—
Loading…
Drag across the chart to select a custom period — all analysis below refocuses to that window.
What this means: Price near 52-week lows confirms what most frameworks are already flagging: the market is discounting deteriorating fundamentals.
What would DHR do to your portfolio?
Add Danaher Corporation at a hypothetical weight and Prism recalculates your whole book:
Risk metrics
Sharpe, Sortino, volatility, max drawdown, beta — before and after.
Sector concentration
How much this shifts your top sector weight and overall diversification.
Archetype tilt
Whether this leans your book more toward Quality, Value, Growth, Deep Value, Income, or Momentum.
DHR is currently tagged:CyclicalFails criteria (21/100)
Portfolio analytics are part of the member experience.
Sign in to run this simulationProbabilistic recommendation· rec-v1.0.0-2026-04
Danaher Corporation · DHR
DHR: 52% estimated probability of outperforming over the next 12M window. 3 of 6 signal families positive (medium confidence). Strongest support: Op margin 23%. Main risk to monitor: 107% above fair value.
Outperform prob.
52%
vs S&P 500 · 12M
Expected return
-4.9% → +19.1%
mid +7.1% / yr
Downside (p20)
-10.1%
stress -20.2%
Data quality
98/100
Excellent
Probabilistic research output, not financial advice. Prism recommendations are based on available data, historical relationships, and model assumptions. They do not guarantee future returns. Conduct independent due diligence before any investment decision.
Backtested and similar-setup statistics may be affected by survivorship bias, look-ahead bias, overfitting, transaction costs, liquidity constraints, and data limitations. Probability estimates are anchored heuristics — not validated forecasts — until the walk-forward backtest pipeline is in place.
Prism Score
Composite 55/100. Strongest contribution from quality; weakest from valuation.
Composite
55
/ 100
Deep valueval.
73/ 100
P/B 2.23× · FCF yield 3.9%
Margin of safetyval.
0/ 100
107% above fair value
Bull · base · bear scenarios
Three plausible paths over a 5-year horizon.
Indicative only. Probabilities are model-implied weights for stress-testing — not forecasts.
Bull
~20%$105.19
-8.8% / yr (5y)
A turnaround takes hold: margin recovers toward peer averages, revenue stabilises, and the market re-prices the asset value rather than the running earnings.
Drivers
- • Margin expands by 200–400 bps from 23%
- • Stranded asset value crystallises
- • Multiple re-rates one full turn higher
Base
~45%$80.92
-13.5% / yr (5y)
No deterioration, no surprise re-acceleration. 23% operating margin and 4% top-line growth chug along; the multiple slowly converges to the central fair-value estimate.
Global value comparison
Danaher Corporation vs sector medians — GCC, MENA, and Global ex-US.
Sector: Healthcare. MENA-aware investors can sanity-check whether the US name is offering value relative to regional peers.
| Metric | DHR | GCC median | MENA median | Global ex-US |
|---|---|---|---|---|
| P/E (TTM) | — | 24.0× | — | 20.0× |
| P/B | 2.23× | 4.80× | — | 3.80× |
| Dividend yield | 0.96% | 1.40% | — | 1.80% |
| ROE | 7.1% |
Earnings reaction explainer
DHR blew past estimates by 12.2%.
Reported EPS $2.06 vs $1.84 expected — well outside the normal beat-and-raise band. The market typically rewards a print this size only if it is read as durable, not one-off. Trailing operating margin: 22.9%.
- Growth investorsPositive
Confirms operating leverage — 10% trailing EPS growth + a beat of this size is the pattern that drives multi-year re-rates.
- Quality investorsPositive
If ROE (7%) and operating margin (23%) are stable or rising, the beat is consistent with compounding rather than one-off.
- Value investorsNegative
Outsized beats on thin trailing quality often invite multiple expansion that doesn't survive the next print.
News & events
Next earnings
Tue, Jul 21 · consensus EPS $1.84 · last actual $2.06
Danaher Digital Transformation Strategy Analysis Report 2026: Technology Focus and Initiatives, Partnerships and Acquisitions, ICT Budget & Contracts, Tech Ecosystem
GlobeNewswire · just now
Chicago health department leaves millions of federal COVID dollars on the table
Chicago Tribune · just now
Is Danaher (DHR) Pricing Look Interesting After Recent Life Sciences Portfolio Focus News
Key Metrics at a Glance
P/E Ratio (TTM)
N/A
PEG Ratio
1.09
P/B Ratio
2.23
EPS Growth
9.8%
Revenue Growth
3.7%
Debt / Equity
0.37
Net Cash / Share
$-19.76
Return on Equity
7.1%
Gross Margin
59.0%
Operating Margin
22.9%
FCF / Share
$6.45
Current Ratio
1.87